Neuberger Berman Group
CTKB icon

Neuberger Berman Group’s Cytek Biosciences CTKB Stock Holding History

Neuberger Berman Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.1K Sell
11,229
-1,175
-9% -$5.55K ﹤0.01% 2116
2025
Q4 		$62.6K Buy
+12,404
New +$57.6K ﹤0.01% 2040
2025
Q2 		– Sell
-13,972
Closed -$56K – 2068
2025
Q1 		$56K Buy
+13,972
New +$72.4K ﹤0.01% 1908

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Neuberger Berman Group's CTKB Position: Q1 2026 in Review

Neuberger Berman Group reduced its Cytek Biosciences (CTKB) stake by 9.5% in Q1 2026, selling an estimated $5.55K and leaving 11,229 shares worth $49.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2116.

Neuberger Berman Group first reported a position in CTKB in Q1 2025 and has held it in 3 quarters since. The position peaked at $62.6K in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Neuberger Berman Group held 11,229 shares of Cytek Biosciences worth $49.1K as of Q1 2026.
  • Neuberger Berman Group sold 1,175 Cytek Biosciences shares in Q1 2026, an estimated $5.55K.
  • Cytek Biosciences made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #2116 holding.
  • Neuberger Berman Group first reported a position in Cytek Biosciences in Q1 2025 and has held it in 3 quarters since.
  • Neuberger Berman Group's Cytek Biosciences position peaked at $62.6K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.